The board meeting for Alnylam Pharmaceuticals Inc is scheduled for today, for the purpose of Alnylam Webcast to Discuss Results from the KARDIA-3 Phase 2 Study of ZilebesiranSee details
Alnylam Pharmaceuticals Inc has a share price target of US$ 424, revenue growth forecast of 55.8%, and profit growth estimate of 145.6% for FY25, based on top 32 analyst calls.